Fuzeon

— THERAPEUTIC CATEGORIES —
  • Viral infections

Fuzeon Generic Name & Formulations

General Description

Enfuvirtide 108mg/vial; pwd for SC inj after reconstitution; preservative-free.

Pharmacological Class

Fusion inhibitor.

How Supplied

Kit—1 (60 vials w. supplies)

Manufacturer

Generic Availability

NO

Fuzeon Indications

Indications

Treatment of HIV-1 infection, in combination with other antiretroviral agents, in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

Fuzeon Dosage and Administration

Adult

Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). Rotate inj sites. >16yrs: 90mg twice daily.

Children

<6yrs: limited data available. Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). Rotate inj sites. 6–16yrs: 2mg/kg twice daily; max 90mg twice daily.

Fuzeon Contraindications

Not Applicable

Fuzeon Boxed Warnings

Not Applicable

Fuzeon Warnings/Precautions

Warnings/Precautions

Discontinue if hypersensitivity occurs; do not rechallenge. Instruct patients on proper use of Biojector 2000 needle-free device. Monitor for pneumonia (esp. if low initial CD4 cell count, high initial viral load, IV drug use, history of lung disease, or smoker). Coagulation disorders. Renal insufficiency (CrCl <35mL/min). Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Fuzeon Pharmacokinetics

See Literature

Fuzeon Interactions

Interactions

Increased risk of post-injection bleed with concomitant anticoagulants. May cause false (+) ELISA test for HIV.

Fuzeon Adverse Reactions

Adverse Reactions

Local inj site reactions, diarrhea, nausea, fatigue; pneumonia, hypersensitivity reactions, immune reconstitution syndrome, autoimmune disorders.

Fuzeon Clinical Trials

See Literature

Fuzeon Note

Notes

Register pregnant patients exposed to enfuvirtide by calling (800) 258-4263.

Fuzeon Patient Counseling

See Literature